Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 4,764 shares at $187.37 ($872K) on 2018-07-09, disclosed to the SEC on 2018-07-11.
Open-market sale of $872k LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $185.34 | 300 | $56K | 6.4% |
| 2 | $186.19 | 200 | $37K | 4.3% |
| 3 | $187.37 | 641 | $120K | 13.8% |
| 4 | $187.37 | 641 | $120K | 13.8% |
| 5 | $188.04 | 200 | $38K | 4.3% |
| 6 | $189.12 | 100 |
| $19K |
| 2.2% |
| 7 | $191.64 | 100 | $19K | 2.2% |
| 8 | $178.39 | 680 | $121K | 13.9% |
| 9 | $178.39 | 680 | $121K | 13.9% |
| 10 | $179.50 | 361 | $65K | 7.4% |
| 11 | $179.50 | 361 | $65K | 7.4% |
| 12 | $180.95 | 300 | $54K | 6.2% |
| 13 | $181.96 | 100 | $18K | 2.1% |
| 14 | $183.19 | 100 | $18K | 2.1% |
| Total | $182.99 avg | 4,764 | $872K | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |